The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
Publication Title
European journal of cancer (Oxford, England : 1990)
Document Type
Article
Publication Date
2-1-2024
Keywords
Humans; CTLA-4 Antigen; T-Lymphocytes, Cytotoxic; Neoplasms; Italy; Immunotherapy; oregon; chiles
Abstract
The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council, included a focus on the future of integrating and expanding the use of targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The conference members exchanged their views on the lessons from targeting CTLA-4 and compared the effect to the impact of blocking Programmed cell death protein 1 (PD1) or its ligand (PDL1). The increasing experience with both therapeutic approaches and their combination suggests that targeting CTLA-4 may lead to more durable responses for a sizeable proportion of patients, though the specific mechanism is not entirely understood. Overcoming toxicity of blocking CTLA-4 is currently being addressed with different doses and dose regimens, especially when combined with PD1/PDL1 blocking antibodies. Novel therapeutics targeting CTLA-4 hold the promise to reduce toxicities and thus allow different combination strategies in the future. On the whole, the consent was that targeting CTLA-4 remains an important strategy to improve the efficacy of cancer immunotherapies.
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
DOI
10.1016/j.ejca.2023.113501
